Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;80(1-2):1–8. doi: 10.1038/sj.bjc.6690312

Retinoids: present role and future potential

T R J Evans 1, S B Kaye 1
PMCID: PMC2362988  PMID: 10389969

Abstract

Vitamin A and its biologically active derivatives, retinal and retinoic acid (RA), together with a large repertoire of synthetic analogues are collectively referred to as retinoids. Naturally occurring retinoids regulate the growth and differentiation of a wide variety of cell types and play a crucial role in the physiology of vision and as morphogenic agents during embryonic development. Retinoids and their analogues have been evaluated as chemoprevention agents, and also in the management of acute promyelocytic leukaemia. Retinoids exert most of their effects by binding to specific receptors and modulating gene expression. The development of new active retinoids and the identification of two distinct families of retinoid receptors has led to an increased understanding of the cellular effects of activation of these receptors. In this article we review the use of retinoids in chemoprevention strategies, discuss the cellular consequences of activated retinoid receptors, and speculate on how our increasing understanding of retinoid-induced signalling pathways may contribute to future therapeutic strategies in the management of malignant disease. © 1999 Cancer Research Campaign

Keywords: differentiation, apoptosis, drug resistance, retinoids

Full Text

The Full Text of this article is available as a PDF (135.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allenby G., Bocquel M. T., Saunders M., Kazmer S., Speck J., Rosenberger M., Lovey A., Kastner P., Grippo J. F., Chambon P. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30–34. doi: 10.1073/pnas.90.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anzano M. A., Byers S. W., Smith J. M., Peer C. W., Mullen L. T., Brown C. C., Roberts A. B., Sporn M. B. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 1994 Sep 1;54(17):4614–4617. [PubMed] [Google Scholar]
  3. Arnold A., Ayoub J., Douglas L., Hoogendoorn P., Skingley L., Gelmon K., Hirsh V., Eisenhauer E. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1994 Feb 16;86(4):306–309. doi: 10.1093/jnci/86.4.306. [DOI] [PubMed] [Google Scholar]
  4. Atencia R., García-Sanz M., Unda F., Aréchaga J. Apoptosis during retinoic acid-induced differentiation of F9 embryonal carcinoma cells. Exp Cell Res. 1994 Oct;214(2):663–667. doi: 10.1006/excr.1994.1304. [DOI] [PubMed] [Google Scholar]
  5. Bavinck J. N., Tieben L. M., Van der Woude F. J., Tegzess A. M., Hermans J., ter Schegget J., Vermeer B. J. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995 Aug;13(8):1933–1938. doi: 10.1200/JCO.1995.13.8.1933. [DOI] [PubMed] [Google Scholar]
  6. Benner S. E., Pajak T. F., Lippman S. M., Earley C., Hong W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst. 1994 Jan 19;86(2):140–141. doi: 10.1093/jnci/86.2.140. [DOI] [PubMed] [Google Scholar]
  7. Bolla M., Lefur R., Ton Van J., Domenge C., Badet J. M., Koskas Y., Laplanche A. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer. 1994;30A(6):767–772. doi: 10.1016/0959-8049(94)90290-9. [DOI] [PubMed] [Google Scholar]
  8. Bollag W., Majewski S., Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia. 1994;8 (Suppl 3):S11–S15. [PubMed] [Google Scholar]
  9. Caliaro M. J., Vitaux P., Lafon C., Lochon I., Néhmé A., Valette A., Canal P., Bugat R., Jozan S. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer. 1997;75(3):333–340. doi: 10.1038/bjc.1997.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Castaigne S., Chomienne C., Daniel M. T., Ballerini P., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 1990 Nov 1;76(9):1704–1709. [PubMed] [Google Scholar]
  11. Chambon P. The molecular and genetic dissection of the retinoid signaling pathway. Recent Prog Horm Res. 1995;50:317–332. doi: 10.1016/b978-0-12-571150-0.50019-6. [DOI] [PubMed] [Google Scholar]
  12. Chen J. D., Evans R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995 Oct 5;377(6548):454–457. doi: 10.1038/377454a0. [DOI] [PubMed] [Google Scholar]
  13. Chen J. Y., Clifford J., Zusi C., Starrett J., Tortolani D., Ostrowski J., Reczek P. R., Chambon P., Gronemeyer H. Two distinct actions of retinoid-receptor ligands. Nature. 1996 Aug 29;382(6594):819–822. doi: 10.1038/382819a0. [DOI] [PubMed] [Google Scholar]
  14. Chen Z. X., Xue Y. Q., Zhang R., Tao R. F., Xia X. M., Li C., Wang W., Zu W. Y., Yao X. Z., Ling B. J. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood. 1991 Sep 15;78(6):1413–1419. [PubMed] [Google Scholar]
  15. Chiesa F., Tradati N., Marazza M., Rossi N., Boracchi P., Mariani L., Formelli F., Giardini R., Costa A., De Palo G. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl. 1993;17F:255–261. doi: 10.1002/jcb.240531038. [DOI] [PubMed] [Google Scholar]
  16. Colston K. W., Mackay A. G., James S. Y., Binderup L., Chander S., Coombes R. C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol. 1992 Dec 15;44(12):2273–2280. doi: 10.1016/0006-2952(92)90669-a. [DOI] [PubMed] [Google Scholar]
  17. Costa A., De Palo G., Decensi A., Formelli F., Chiesa F., Nava M., Camerini T., Marubini E., Veronesi U. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Ann N Y Acad Sci. 1995 Sep 30;768:148–162. doi: 10.1111/j.1749-6632.1995.tb12118.x. [DOI] [PubMed] [Google Scholar]
  18. Costa A., Formelli F., Chiesa F., Decensi A., De Palo G., Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 1994 Apr 1;54(7 Suppl):2032s–2037s. [PubMed] [Google Scholar]
  19. Creek K. E., Jenkins G. R., Khan M. A., Batova A., Hodam J. R., Tolleson W. H., Pirisi L. Retinoic acid suppresses human papillomavirus type 16 (HPV16)-mediated transformation of human keratinocytes and inhibits the expression of the HPV16 oncogenes. Adv Exp Med Biol. 1994;354:19–35. doi: 10.1007/978-1-4899-0939-8_2. [DOI] [PubMed] [Google Scholar]
  20. Darwiche N., Scita G., Jones C., Rutberg S., Greenwald E., Tennenbaum T., Collins S. J., De Luca L. M., Yuspa S. H. Loss of retinoic acid receptors in mouse skin and skin tumors is associated with activation of the ras(Ha) oncogene and high risk for premalignant progression. Cancer Res. 1996 Nov 1;56(21):4942–4949. [PubMed] [Google Scholar]
  21. Dey A., Minucci S., Ozato K. Ligand-dependent occupancy of the retinoic acid receptor beta 2 promoter in vivo. Mol Cell Biol. 1994 Dec;14(12):8191–8201. doi: 10.1128/mcb.14.12.8191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Dhingra K., Papadopoulos N., Lippman S., Lotan R., Legha S. S. Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma. Invest New Drugs. 1993 Feb;11(1):39–43. doi: 10.1007/BF00873908. [DOI] [PubMed] [Google Scholar]
  23. Durand B., Saunders M., Leroy P., Leid M., Chambon P. All-trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. Cell. 1992 Oct 2;71(1):73–85. doi: 10.1016/0092-8674(92)90267-g. [DOI] [PubMed] [Google Scholar]
  24. Edwards L., Jaffe P. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol. 1990 Apr;126(4):494–499. [PubMed] [Google Scholar]
  25. Eisenhauer E. A., Lippman S. M., Kavanagh J. J., Parades-Espinoza M., Arnold A., Hong W. K., Massimini G., Schleuniger U., Bollag W., Holdener E. E. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia. 1994;8 (Suppl 3):S38–S41. [PubMed] [Google Scholar]
  26. Elstner E., Linker-Israeli M., Umiel T., Le J., Grillier I., Said J., Shintaku I. P., Krajewski S., Reed J. C., Binderup L. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 1996 Aug 1;56(15):3570–3576. [PubMed] [Google Scholar]
  27. Evans R. M., Hollenberg S. M. Zinc fingers: gilt by association. Cell. 1988 Jan 15;52(1):1–3. doi: 10.1016/0092-8674(88)90522-3. [DOI] [PubMed] [Google Scholar]
  28. Evans R. M. The steroid and thyroid hormone receptor superfamily. Science. 1988 May 13;240(4854):889–895. doi: 10.1126/science.3283939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fan S., el-Deiry W. S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace A. J., Jr, Magrath I., Kohn K. W., O'Connor P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994 Nov 15;54(22):5824–5830. [PubMed] [Google Scholar]
  30. Fanjul A. N., Bouterfa H., Dawson M., Pfahl M. Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res. 1996 Apr 1;56(7):1571–1577. [PubMed] [Google Scholar]
  31. Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P., Lamy T., Tilly H., Guerci A., Maloisel F. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood. 1992 Nov 1;80(9):2176–2181. [PubMed] [Google Scholar]
  32. Fontana J. A. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol. 1987;55(3):136–144. doi: 10.1159/000163409. [DOI] [PubMed] [Google Scholar]
  33. Fontana J. A., Miranda D., Mezu A. B. Retinoic acid inhibition of human breast carcinoma proliferation is accompanied by inhibition of the synthesis of a Mr 39,000 protein. Cancer Res. 1990 Apr 1;50(7):1977–1982. [PubMed] [Google Scholar]
  34. Frankel S. R., Eardley A., Heller G., Berman E., Miller W. H., Jr, Dmitrovsky E., Warrell R. P., Jr All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med. 1994 Feb 15;120(4):278–286. doi: 10.7326/0003-4819-120-4-199402150-00004. [DOI] [PubMed] [Google Scholar]
  35. Freedman L. P. Anatomy of the steroid receptor zinc finger region. Endocr Rev. 1992 May;13(2):129–145. doi: 10.1210/edrv-13-2-129. [DOI] [PubMed] [Google Scholar]
  36. Gianni M., Terao M., Fortino I., LiCalzi M., Viggiano V., Barbui T., Rambaldi A., Garattini E. Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood. 1997 Feb 1;89(3):1001–1012. [PubMed] [Google Scholar]
  37. Giguere V., Ong E. S., Segui P., Evans R. M. Identification of a receptor for the morphogen retinoic acid. Nature. 1987 Dec 17;330(6149):624–629. doi: 10.1038/330624a0. [DOI] [PubMed] [Google Scholar]
  38. Giguère V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev. 1994 Feb;15(1):61–79. doi: 10.1210/edrv-15-1-61. [DOI] [PubMed] [Google Scholar]
  39. Gorry P., Lufkin T., Dierich A., Rochette-Egly C., Décimo D., Dollé P., Mark M., Durand B., Chambon P. The cellular retinoic acid binding protein I is dispensable. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9032–9036. doi: 10.1073/pnas.91.19.9032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Gottardis M. M., Bischoff E. D., Shirley M. A., Wagoner M. A., Lamph W. W., Heyman R. A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 1996 Dec 15;56(24):5566–5570. [PubMed] [Google Scholar]
  41. Gottardis M. M., Lamph W. W., Shalinsky D. R., Wellstein A., Heyman R. A. The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat. 1996;38(1):85–96. doi: 10.1007/BF01803787. [DOI] [PubMed] [Google Scholar]
  42. Gucev Z. S., Oh Y., Kelley K. M., Rosenfeld R. G. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996 Apr 1;56(7):1545–1550. [PubMed] [Google Scholar]
  43. Guchelaar H. J., Timmer-Bosscha H., Dam-Meiring A., Uges D. R., Oosterhuis J. W., de Vries E. G., Mulder N. H. Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J Cancer. 1993 Sep 30;55(3):442–447. doi: 10.1002/ijc.2910550320. [DOI] [PubMed] [Google Scholar]
  44. Hallum A. V., 3rd, Alberts D. S., Lippman S. M., Inclan L., Shamdas G. J., Childers J. M., Surwit E. A., Modiano M., Hatch K. D. Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix. Gynecol Oncol. 1995 Mar;56(3):382–386. doi: 10.1006/gyno.1995.1067. [DOI] [PubMed] [Google Scholar]
  45. Halpern A. C., Schuchter L. M., Elder D. E., Guerry D., 4th, Elenitsas R., Trock B., Matozzo I. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol. 1994 May;12(5):1028–1035. doi: 10.1200/JCO.1994.12.5.1028. [DOI] [PubMed] [Google Scholar]
  46. Han J. Highlights of the cancer chemoprevention studies in China. Prev Med. 1993 Sep;22(5):712–722. doi: 10.1006/pmed.1993.1065. [DOI] [PubMed] [Google Scholar]
  47. Harant H., Korschineck I., Krupitza G., Fazeny B., Dittrich C., Grunt T. W. Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Br J Cancer. 1993 Sep;68(3):530–536. doi: 10.1038/bjc.1993.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Higashimoto Y., Ohata M., Nishio K., Iwamoto Y., Fujimoto H., Uetani K., Suruda T., Nakamura Y., Funasako M., Saijo N. 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 1996 Sep-Oct;16(5A):2653–2659. [PubMed] [Google Scholar]
  49. Hong W. K., Endicott J., Itri L. M., Doos W., Batsakis J. G., Bell R., Fofonoff S., Byers R., Atkinson E. N., Vaughan C. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986 Dec 11;315(24):1501–1505. doi: 10.1056/NEJM198612113152401. [DOI] [PubMed] [Google Scholar]
  50. Hong W. K., Lippman S. M., Itri L. M., Karp D. D., Lee J. S., Byers R. M., Schantz S. P., Kramer A. M., Lotan R., Peters L. J. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990 Sep 20;323(12):795–801. doi: 10.1056/NEJM199009203231205. [DOI] [PubMed] [Google Scholar]
  51. Horwitz K. B., Jackson T. A., Bain D. L., Richer J. K., Takimoto G. S., Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996 Oct;10(10):1167–1177. doi: 10.1210/mend.10.10.9121485. [DOI] [PubMed] [Google Scholar]
  52. Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988 Aug;72(2):567–572. [PubMed] [Google Scholar]
  53. Kalemkerian G. P., Slusher R., Ramalingam S., Gadgeel S., Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst. 1995 Nov 15;87(22):1674–1680. doi: 10.1093/jnci/87.22.1674. [DOI] [PubMed] [Google Scholar]
  54. Kanamaru A., Takemoto Y., Tanimoto M., Murakami H., Asou N., Kobayashi T., Kuriyama K., Ohmoto E., Sakamaki H., Tsubaki K. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood. 1995 Mar 1;85(5):1202–1206. [PubMed] [Google Scholar]
  55. Kliewer S. A., Umesono K., Mangelsdorf D. J., Evans R. M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature. 1992 Jan 30;355(6359):446–449. doi: 10.1038/355446a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Kolla V., Lindner D. J., Xiao W., Borden E. C., Kalvakolanu D. V. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem. 1996 May 3;271(18):10508–10514. doi: 10.1074/jbc.271.18.10508. [DOI] [PubMed] [Google Scholar]
  57. Kondo S., Barna B. P., Kondo Y., Tanaka Y., Casey G., Liu J., Morimura T., Kaakaji R., Peterson J. W., Werbel B. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene. 1996 Sep 19;13(6):1279–1285. [PubMed] [Google Scholar]
  58. Kurokawa R., Söderström M., Hörlein A., Halachmi S., Brown M., Rosenfeld M. G., Glass C. K. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature. 1995 Oct 5;377(6548):451–454. doi: 10.1038/377451a0. [DOI] [PubMed] [Google Scholar]
  59. Laudet V., Hänni C., Coll J., Catzeflis F., Stéhelin D. Evolution of the nuclear receptor gene superfamily. EMBO J. 1992 Mar;11(3):1003–1013. doi: 10.1002/j.1460-2075.1992.tb05139.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Le-Ruppert K., Masters J. R., Knuechel R., Seegers S., Tainsky M. A., Hofstaedter F., Buettner R. The effect of retinoic acid on chemosensitivity of PA-1 human teratocarcinoma cells and its modulation by an activated N-ras oncogene. Int J Cancer. 1992 Jun 19;51(4):646–651. doi: 10.1002/ijc.2910510423. [DOI] [PubMed] [Google Scholar]
  61. Lee J. S., Lippman S. M., Benner S. E., Lee J. J., Ro J. Y., Lukeman J. M., Morice R. C., Peters E. J., Pang A. C., Fritsche H. A., Jr Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol. 1994 May;12(5):937–945. doi: 10.1200/JCO.1994.12.5.937. [DOI] [PubMed] [Google Scholar]
  62. Lee P. P., Lee M. T., Darcy K. M., Shudo K., Ip M. M. Modulation of normal mammary epithelial cell proliferation, morphogenesis, and functional differentiation by retinoids: a comparison of the retinobenzoic acid derivative RE80 with retinoic acid. Endocrinology. 1995 Apr;136(4):1707–1717. doi: 10.1210/endo.136.4.7895682. [DOI] [PubMed] [Google Scholar]
  63. Liebermann D. A., Hoffman B., Steinman R. A. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene. 1995 Jul 6;11(1):199–210. [PubMed] [Google Scholar]
  64. Lippman S. M., Batsakis J. G., Toth B. B., Weber R. S., Lee J. J., Martin J. W., Hays G. L., Goepfert H., Hong W. K. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993 Jan 7;328(1):15–20. doi: 10.1056/NEJM199301073280103. [DOI] [PubMed] [Google Scholar]
  65. Lippman S. M., Clayman G. L., Huber M. H., Benner S. E., Hong W. K. Biology and reversal of aerodigestive tract carcinogenesis. Cancer Treat Res. 1995;74:89–115. doi: 10.1007/978-1-4615-2023-8_5. [DOI] [PubMed] [Google Scholar]
  66. Liu M., Iavarone A., Freedman L. P. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem. 1996 Dec 6;271(49):31723–31728. doi: 10.1074/jbc.271.49.31723. [DOI] [PubMed] [Google Scholar]
  67. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 1996 Jul;10(9):1031–1039. doi: 10.1096/fasebj.10.9.8801164. [DOI] [PubMed] [Google Scholar]
  68. Lotan R. Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res. 1994 Apr 1;54(7 Suppl):1987s–1990s. [PubMed] [Google Scholar]
  69. Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman D. E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994 Nov 4;266(5186):807–810. doi: 10.1126/science.7973635. [DOI] [PubMed] [Google Scholar]
  70. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  71. Mader S., Leroy P., Chen J. Y., Chambon P. Multiple parameters control the selectivity of nuclear receptors for their response elements. Selectivity and promiscuity in response element recognition by retinoic acid receptors and retinoid X receptors. J Biol Chem. 1993 Jan 5;268(1):591–600. [PubMed] [Google Scholar]
  72. Mangelsdorf D. J., Borgmeyer U., Heyman R. A., Zhou J. Y., Ong E. S., Oro A. E., Kakizuka A., Evans R. M. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev. 1992 Mar;6(3):329–344. doi: 10.1101/gad.6.3.329. [DOI] [PubMed] [Google Scholar]
  73. Mangelsdorf D. J., Umesono K., Kliewer S. A., Borgmeyer U., Ong E. S., Evans R. M. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell. 1991 Aug 9;66(3):555–561. doi: 10.1016/0092-8674(81)90018-0. [DOI] [PubMed] [Google Scholar]
  74. Marth C., Daxenbichler G., Dapunt O. Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst. 1986 Dec;77(6):1197–1202. [PubMed] [Google Scholar]
  75. Martin S. J., Bradley J. G., Cotter T. G. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol. 1990 Mar;79(3):448–453. doi: 10.1111/j.1365-2249.1990.tb08110.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Matikainen S., Ronni T., Hurme M., Pine R., Julkunen I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood. 1996 Jul 1;88(1):114–123. [PubMed] [Google Scholar]
  77. Meyskens F. L., Jr, Surwit E., Moon T. E., Childers J. M., Davis J. R., Dorr R. T., Johnson C. S., Alberts D. S. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst. 1994 Apr 6;86(7):539–543. doi: 10.1093/jnci/86.7.539. [DOI] [PubMed] [Google Scholar]
  78. Miller G. J., Stapleton G. E., Ferrara J. A., Lucia M. S., Pfister S., Hedlund T. E., Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1992 Feb 1;52(3):515–520. [PubMed] [Google Scholar]
  79. Miller V. A., Benedetti F. M., Rigas J. R., Verret A. L., Pfister D. G., Straus D., Kris M. G., Crisp M., Heyman R., Loewen G. R. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol. 1997 Feb;15(2):790–795. doi: 10.1200/JCO.1997.15.2.790. [DOI] [PubMed] [Google Scholar]
  80. Moasser M. M., DeBlasio A., Dmitrovsky E. Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptor gamma in human teratocarcinomas. Oncogene. 1994 Mar;9(3):833–840. [PubMed] [Google Scholar]
  81. Moon T. E., Levine N., Cartmel B., Bangert J. L. Retinoids in prevention of skin cancer. Cancer Lett. 1997 Mar 19;114(1-2):203–205. doi: 10.1016/s0304-3835(97)04663-6. [DOI] [PubMed] [Google Scholar]
  82. Nagpal S., Saunders M., Kastner P., Durand B., Nakshatri H., Chambon P. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell. 1992 Sep 18;70(6):1007–1019. doi: 10.1016/0092-8674(92)90250-g. [DOI] [PubMed] [Google Scholar]
  83. Nagy L., Thomázy V. A., Shipley G. L., Fésüs L., Lamph W., Heyman R. A., Chandraratna R. A., Davies P. J. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol. 1995 Jul;15(7):3540–3551. doi: 10.1128/mcb.15.7.3540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Ohno R., Yoshida H., Fukutani H., Naoe T., Ohshima T., Kyo T., Endoh N., Fujimoto T., Kobayashi T., Hiraoka A. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare. Leukemia. 1993 Nov;7(11):1722–1727. [PubMed] [Google Scholar]
  85. Oridate N., Lotan D., Xu X. C., Hong W. K., Lotan R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 1996 May;2(5):855–863. [PubMed] [Google Scholar]
  86. Pastorino U., Infante M., Maioli M., Chiesa G., Buyse M., Firket P., Rosmentz N., Clerici M., Soresi E., Valente M. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol. 1993 Jul;11(7):1216–1222. doi: 10.1200/JCO.1993.11.7.1216. [DOI] [PubMed] [Google Scholar]
  87. Perlmann T., Evans R. M. Nuclear receptors in Sicily: all in the famiglia. Cell. 1997 Aug 8;90(3):391–397. doi: 10.1016/s0092-8674(00)80498-5. [DOI] [PubMed] [Google Scholar]
  88. Petkovich M., Brand N. J., Krust A., Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature. 1987 Dec 3;330(6147):444–450. doi: 10.1038/330444a0. [DOI] [PubMed] [Google Scholar]
  89. Piacentini M., Annicchiarico-Petruzzelli M., Oliverio S., Piredda L., Biedler J. L., Melino E. Phenotype-specific "tissue" transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis. Int J Cancer. 1992 Sep 9;52(2):271–278. doi: 10.1002/ijc.2910520220. [DOI] [PubMed] [Google Scholar]
  90. Pratt M. A., Deonarine D., Teixeira C., Novosad D., Tate B. F., Grippo J. F. The AF-2 region of the retinoic acid receptor alpha mediates retinoic acid inhibition of estrogen receptor function in breast cancer cells. J Biol Chem. 1996 Aug 23;271(34):20346–20352. doi: 10.1074/jbc.271.34.20346. [DOI] [PubMed] [Google Scholar]
  91. Prout G. R., Jr, Barton B. A. 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem Suppl. 1992;16I:148–152. [PubMed] [Google Scholar]
  92. Reichel H., Koeffler H. P., Norman A. W. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989 Apr 13;320(15):980–991. doi: 10.1056/NEJM198904133201506. [DOI] [PubMed] [Google Scholar]
  93. Rinaldi D. A., Lippman S. M., Burris H. A., 3rd, Chou C., Von Hoff D. D., Hong W. K. Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer. Anticancer Drugs. 1993 Feb;4(1):33–36. doi: 10.1097/00001813-199302000-00004. [DOI] [PubMed] [Google Scholar]
  94. Rishi A. K., Gerald T. M., Shao Z. M., Li X. S., Baumann R. G., Dawson M. I., Fontana J. A. Regulation of the human retinoic acid receptor alpha gene in the estrogen receptor negative human breast carcinoma cell lines SKBR-3 and MDA-MB-435. Cancer Res. 1996 Nov 15;56(22):5246–5252. [PubMed] [Google Scholar]
  95. Roberts A. B., Sporn M. B. Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-beta. Cancer Surv. 1992;14:205–220. [PubMed] [Google Scholar]
  96. Roman S. D., Ormandy C. J., Manning D. L., Blamey R. W., Nicholson R. I., Sutherland R. L., Clarke C. L. Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Res. 1993 Dec 15;53(24):5940–5945. [PubMed] [Google Scholar]
  97. Rook A. H., Jaworsky C., Nguyen T., Grossman R. A., Wolfe J. T., Witmer W. K., Kligman A. M. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation. 1995 Mar 15;59(5):714–719. doi: 10.1097/00007890-199503150-00013. [DOI] [PubMed] [Google Scholar]
  98. Rubin M., Fenig E., Rosenauer A., Menendez-Botet C., Achkar C., Bentel J. M., Yahalom J., Mendelsohn J., Miller W. H., Jr 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res. 1994 Dec 15;54(24):6549–6556. [PubMed] [Google Scholar]
  99. Sacks P. G., Harris D., Chou T. C. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer. 1995 May 4;61(3):409–415. doi: 10.1002/ijc.2910610322. [DOI] [PubMed] [Google Scholar]
  100. Schadendorf D., Kern M. A., Artuc M., Pahl H. L., Rosenbach T., Fichtner I., Nürnberg W., Stüting S., von Stebut E., Worm M. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol. 1996 Dec;135(6 Pt 2):1889–1898. doi: 10.1083/jcb.135.6.1889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Scita G., Darwiche N., Greenwald E., Rosenberg M., Politi K., De Luca L. M. Retinoic acid down-regulation of fibronectin and retinoic acid receptor alpha proteins in NIH-3T3 cells. Blocks of this response by ras transformation. J Biol Chem. 1996 Mar 15;271(11):6502–6508. doi: 10.1074/jbc.271.11.6502. [DOI] [PubMed] [Google Scholar]
  102. Selvakumaran M., Lin H. K., Sjin R. T., Reed J. C., Liebermann D. A., Hoffman B. The novel primary response gene MyD118 and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor beta 1-induced apoptosis of myeloid leukemia cells. Mol Cell Biol. 1994 Apr;14(4):2352–2360. doi: 10.1128/mcb.14.4.2352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Shabahang M., Buras R. R., Davoodi F., Schumaker L. M., Nauta R. J., Uskokovic M. R., Brenner R. V., Evans S. R. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res. 1994 Aug 1;54(15):4057–4064. [PubMed] [Google Scholar]
  104. Shalinsky D. R., Bischoff E. D., Gregory M. L., Lamph W. W., Heyman R. A., Hayes J. S., Thomazy V., Davies P. J. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res. 1996 Mar;2(3):511–520. [PubMed] [Google Scholar]
  105. Shalinsky D. R., Bischoff E. D., Lamph W. W., Zhang L., Boehm M. F., Davies P. J., Nadzan A. M., Heyman R. A. A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res. 1997 Jan 1;57(1):162–168. [PubMed] [Google Scholar]
  106. Shao Z. M., Dawson M. I., Li X. S., Rishi A. K., Sheikh M. S., Han Q. X., Ordonez J. V., Shroot B., Fontana J. A. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene. 1995 Aug 3;11(3):493–504. [PubMed] [Google Scholar]
  107. Sheikh M. S., Shao Z. M., Li X. S., Dawson M., Jetten A. M., Wu S., Conley B. A., Garcia M., Rochefort H., Fontana J. A. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem. 1994 Aug 26;269(34):21440–21447. [PubMed] [Google Scholar]
  108. Sheikh M. S., Shao Z. M., Li X. S., Ordonez J. V., Conley B. A., Wu S., Dawson M. I., Han Q. X., Chao W. R., Quick T. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis. 1995 Oct;16(10):2477–2486. doi: 10.1093/carcin/16.10.2477. [DOI] [PubMed] [Google Scholar]
  109. Smith W. C., Nakshatri H., Leroy P., Rees J., Chambon P. A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter. EMBO J. 1991 Aug;10(8):2223–2230. doi: 10.1002/j.1460-2075.1991.tb07758.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Studer U. E., Jenzer S., Biedermann C., Chollet D., Kraft R., von Toggenburg H., Vonbank F. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol. 1995;28(4):284–290. doi: 10.1159/000475068. [DOI] [PubMed] [Google Scholar]
  111. Supino R., Crosti M., Clerici M., Warlters A., Cleris L., Zunino F., Formelli F. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer. 1996 Feb 8;65(4):491–497. doi: 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  112. Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T., Van Dyke T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994 Aug 26;78(4):703–711. doi: 10.1016/0092-8674(94)90534-7. [DOI] [PubMed] [Google Scholar]
  113. Tallman M. S., Andersen J. W., Schiffer C. A., Appelbaum F. R., Feusner J. H., Ogden A., Shepherd L., Willman C., Bloomfield C. D., Rowe J. M. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997 Oct 9;337(15):1021–1028. doi: 10.1056/NEJM199710093371501. [DOI] [PubMed] [Google Scholar]
  114. Thiruvengadam R., Atiba J. O., Azawi S. H. A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer. Invest New Drugs. 1996;14(4):395–401. doi: 10.1007/BF00180817. [DOI] [PubMed] [Google Scholar]
  115. Tsang N. M., Nagasawa H., Li C., Little J. B. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene. 1995 Jun 15;10(12):2403–2408. [PubMed] [Google Scholar]
  116. Voravud N., Lippman S. M., Weber R. S., Rodriquez G. I., Yee D., Dimery I. W., Earley C. L., Von Hoff D. D., Hong W. K. Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer. Invest New Drugs. 1993 Feb;11(1):57–60. doi: 10.1007/BF00873912. [DOI] [PubMed] [Google Scholar]
  117. Warrell R. P., Jr, Frankel S. R., Miller W. H., Jr, Scheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreeff M., Tafuri A., Jakubowski A. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991 May 16;324(20):1385–1393. doi: 10.1056/NEJM199105163242002. [DOI] [PubMed] [Google Scholar]
  118. Widschwendter M., Daxenbichler G., Dapunt O., Marth C. Effects of retinoic acid and gamma-interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. Cancer Res. 1995 May 15;55(10):2135–2139. [PubMed] [Google Scholar]
  119. Wilcken N. R., Musgrove E. A., Sutherland R. L. Different points of action of retinoids and anti-estrogens in G1 phase identified in synchronized T-47D breast cancer cells. Int J Cancer. 1997 Jan 27;70(3):291–296. doi: 10.1002/(sici)1097-0215(19970127)70:3<291::aid-ijc8>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  120. Wu G. S., El-Deiry W. S. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res. 1996 Apr;2(4):623–633. [PubMed] [Google Scholar]
  121. Yang N., Schüle R., Mangelsdorf D. J., Evans R. M. Characterization of DNA binding and retinoic acid binding properties of retinoic acid receptor. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3559–3563. doi: 10.1073/pnas.88.9.3559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Zhang X. K., Hoffmann B., Tran P. B., Graupner G., Pfahl M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature. 1992 Jan 30;355(6359):441–446. doi: 10.1038/355441a0. [DOI] [PubMed] [Google Scholar]
  123. Zugmaier G., Jäger R., Grage B., Gottardis M. M., Havemann K., Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer. 1996 Jun;73(11):1341–1346. doi: 10.1038/bjc.1996.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. de Bruijn D. R., Oerlemans F., Hendriks W., Baats E., Ploemacher R., Wieringa B., Geurts van Kessel A. Normal development, growth and reproduction in cellular retinoic acid binding protein-I (CRABPI) null mutant mice. Differentiation. 1994 Dec;58(2):141–148. doi: 10.1046/j.1432-0436.1995.5820141.x. [DOI] [PubMed] [Google Scholar]
  125. van der Burg B., van der Leede B. M., Kwakkenbos-Isbrücker L., Salverda S., de Laat S. W., van der Saag P. T. Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol Cell Endocrinol. 1993 Feb;91(1-2):149–157. doi: 10.1016/0303-7207(93)90267-n. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES